4.2 Article

Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study

Related references

Note: Only part of the references are listed.
Article Rheumatology

Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience

Serdal Ugurlu et al.

Summary: Anakinra has been proven effective for colchicine-resistant patients with FMF by reducing attack frequency and subclinical inflammation. The study showed a significant decrease in attack frequency and disease severity in patients receiving anakinra treatment, with 71 patients still on treatment and 32% discontinuing due to insufficient response or side effects.

RHEUMATOLOGY (2021)

Article Medicine, General & Internal

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

F. De Benedetti et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Review Rheumatology

EULAR recommendations for the management of familial Mediterranean fever

Seza Ozen et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

Article Rheumatology

Dysregulated mature IL-1β production in familial Mediterranean fever

Kiyoshi Migita et al.

RHEUMATOLOGY (2015)

Article Medicine, General & Internal

Familial Mediterranean Fever Genotype-Phenotype Correlations in Japanese Patients

Kiyoshi Migita et al.

MEDICINE (2014)

Article Medicine, General & Internal

Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever A Randomized Trial

Philip J. Hashkes et al.

ANNALS OF INTERNAL MEDICINE (2012)

Article Medicine, General & Internal

Familial Mediterranean Fever in Japan

Kiyoshi Migita et al.

MEDICINE (2012)